Stay updated on Pembrolizumab with Radium-223 in mCRPC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab with Radium-223 in mCRPC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab with Radium-223 in mCRPC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:32:24.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study evaluating the addition of Pembrolizumab to Radium-223 in metastatic castration-resistant prostate cancer. This change reflects a potential modification or advancement in the treatment approach being studied for this specific disease.
    Difference
    0.1%
    Check dated 2024-06-06T14:27:15.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments. Additionally, the inclusion criteria now specify requirements for histologically confirmed adenocarcinoma of the prostate and castration-resistant prostate cancer with detailed conditions for progression and prior treatments.
    Difference
    56%
    Check dated 2024-05-22T20:33:23.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:23:18.000Z thumbnail image

Stay in the know with updates to Pembrolizumab with Radium-223 in mCRPC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Radium-223 in mCRPC Clinical Trial page.